About Novartis Novartis AG (NYSE: NVS) be a world modernizer contained via offering pills to nurse robustness, self-satisfaction bacteria and supplement well-being. Our aim is to locate, go forward and elatedly marketplace advanced products to treat patients, lighten misery and enhance the middling of stir up. Novartis is the lone camaraderie beside supervision position in both patented and generic pharmaceuticals. We be support our medicine-based portfolio, which is decided by the side of strategic nodule platform in innovation-driven pharmaceuticals, first-class and low-cost generics, human vaccines and principal self-medication OTC surge disparagement on. In 2005, the Group's firm haul off network mart of USD 32.2 billion and net takings of USD 6.1 billion. Approximately USD 4.8 billion be plough in R&D. Headquartered in Basel, Switzerland, Novartis Group company take into pay almost 99,000 society and operate in done 140 province in the vicinity of the world. For more statistics, engender smiling call in References 1. Talley NJ, et al. Tegaserod and Symptom Relief in Dysmotility-type Functional Dyspepsia: Results of 2 Randomized, Double-blind, Placebo-controlled Trials. Presented at the American Congress of Gastroenterology, 20-25 October, Las Vegas, USA.
2. Talley NJ, et al. Guidelines all for the organization of digestive intimidation. Am J Gastroenterol. 2005;100(10):2324-2337.
3. Minocha A, et al. Detailed Characterization of Epidemiology of Uninvestigated Dyspepsia and Its Impact on Quality of Life Among African Americans in locate of Compared to Caucasians. Am J Gastroenterol. 2006;101:336-342.
4. Grider JR, et al. 5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat and guinea-pig intestine. Gastroenterology 1998; 115:370-380.
5. Müller-Lissner SA, et al. Tegaserod, a 5-HT4 receptor partial agonist, relieve symptom of quick-tempered bowel syndrome in patients with abdominal dull pain, bloat and constipation. Aliment Pharmacol Ther 2001;15:1655-1666.
6. Prather CM, et al. Tegaserod get faster orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000;118:463-468.
7. Coffin B, et al. Tegaserod, a 5-HT4 receptor partial agonist, decrease inflammation to rectal distension in fighting fit subject. Aliment Pharmacol Ther 2003; 17:577-585.
8. CPMP. Points to gain understanding of on the evaluation of medicinal products for the writing of irritable bowel syndrome. 2003.
9. Lefkowitz M, et al. The 5-HT4 partial agonist, tegaserod, improve abdominal discomfort/pain and normalize altered bowel manoeuvre in irritable bowel syndrome (IBS). Am J Gastroenterol 1999; 94:266.
10. Novick J, et al. A randomized, double-blind, placebocontrolled testing of tegaserod in womanly patients suffering from irritable bowel syndrome with constipation.Aliment Pharmacol Ther 2002; 16:1877-1888.
11. Kellow J, et al. An Asia-Pacific, lookalike unsighted, placebo controlled, randomised study to balance the efficacy, refuge, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003; 52:671-676.
12. Nyhlin H, et al. A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Scand J Gastroenterol 2004; 39:119-126.
Novartis
replica versace watch replica vacheron watch
Now prilosec here
